X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2918) 2918
Newsletter (1505) 1505
Newspaper Article (877) 877
Magazine Article (99) 99
Transcript (31) 31
Book / eBook (17) 17
Streaming Video (8) 8
Book Review (6) 6
Conference Proceeding (6) 6
Web Resource (6) 6
Book Chapter (5) 5
Dissertation (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
antiparkinsonian agents (5139) 5139
parkinson's disease (2044) 2044
medical research (1218) 1218
medicine, experimental (1192) 1192
research (1062) 1062
drug therapy (989) 989
index medicus (950) 950
humans (894) 894
male (653) 653
neurosciences (625) 625
analysis (624) 624
drugs (573) 573
pharmaceutical industry (563) 563
female (495) 495
clinical neurology (473) 473
animals (456) 456
parkinson disease - drug therapy (439) 439
dopamine (406) 406
aged (393) 393
middle aged (383) 383
movement disorders (382) 382
care and treatment (376) 376
neurology (355) 355
pharmacology & pharmacy (351) 351
parkinsons disease (331) 331
physical fitness (324) 324
product development (299) 299
clinical trials (295) 295
universities and colleges (291) 291
levodopa (276) 276
antiparkinson agents - therapeutic use (264) 264
phenols (253) 253
parkinson’s disease (248) 248
parkinsons-disease (218) 218
rats (203) 203
health aspects (198) 198
neurons (188) 188
brain (182) 182
neurodegenerative diseases (182) 182
alzheimer's disease (176) 176
psychiatry (175) 175
basal ganglia (172) 172
medicine & public health (167) 167
adult (166) 166
parkinson disease - physiopathology (160) 160
development and progression (149) 149
nervous system diseases (137) 137
dopa (134) 134
parkinson disease (133) 133
mice (131) 131
levodopa - therapeutic use (130) 130
risk factors (130) 130
l-dopa (128) 128
aged, 80 and over (120) 120
medical colleges (118) 118
parkinson disease - complications (118) 118
schizophrenia (118) 118
antiparkinson agents - adverse effects (115) 115
disease models, animal (114) 114
nervous system agents (113) 113
dosage and administration (112) 112
pharmacology/toxicology (112) 112
disease (109) 109
antipsychotic drugs (107) 107
dose-response relationship, drug (104) 104
parkinsonism (103) 103
treatment outcome (103) 103
tremor (103) 103
dementia (102) 102
forecasts and trends (101) 101
physiological aspects (100) 100
antiparkinson agents - pharmacology (99) 99
oxidative stress (99) 99
biotechnology industry (97) 97
complications and side effects (96) 96
diagnosis (95) 95
extrapyramidal disorders (95) 95
dopamine - metabolism (94) 94
double-blind (94) 94
internal medicine (93) 93
dyskinesia (92) 92
antiparkinson agents - administration & dosage (91) 91
antidepressants (88) 88
neuroprotection (88) 88
parkinson disease - therapy (88) 88
biomedicine (87) 87
pramipexole (87) 87
usage (87) 87
drug approval (86) 86
monoamine oxidase (86) 86
dopamine receptors (85) 85
rats, sprague-dawley (84) 84
depression, mental (82) 82
patients (82) 82
studies (80) 80
antiparkinsonians (79) 79
parkinson disease - metabolism (79) 79
time factors (78) 78
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5460) 5460
Spanish (9) 9
German (7) 7
Japanese (7) 7
French (2) 2
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of controlled release, ISSN 0168-3659, 2015, Volume 207, pp. 18 - 30
Exosomes are naturally occurring nanosized vesicles that have attracted considerable attention as drug delivery vehicles in the past few years. Exosomes are... 
Oxidative stress | Neuroinflammation | Parkinson's disease | Catalase | Exosomes | Blood–brain barrier | Blood-brain barrier | ALZHEIMERS-DISEASE | REPEATED INJECTIONS | MACROPHAGE DELIVERY | MEDIATED TRANSFER | BLOOD-BRAIN-BARRIER | BIOLOGICAL BARRIERS | CHEMISTRY, MULTIDISCIPLINARY | IN-VITRO | PEGYLATED LIPOSOMES | PHARMACOLOGY & PHARMACY | SUPEROXIDE-DISMUTASE | Antioxidants - chemistry | Antioxidants - metabolism | Oxidopamine | Anti-Inflammatory Agents - metabolism | PC12 Cells | Neuroprotective Agents - metabolism | Drug Carriers | Brain - metabolism | Nanoparticles | Parkinsonian Disorders - metabolism | Parkinsonian Disorders - drug therapy | Antiparkinson Agents - chemistry | Anti-Inflammatory Agents - administration & dosage | Female | Neurons - metabolism | Neuroprotective Agents - administration & dosage | Nanomedicine | Disease Models, Animal | Neuroprotective Agents - chemistry | Mice, Inbred C57BL | Solubility | Rats | Technology, Pharmaceutical - methods | Parkinsonian Disorders - chemically induced | Administration, Intranasal | Chemistry, Pharmaceutical | Brain - drug effects | Catalase - metabolism | Catalase - administration & dosage | Animals | Anti-Inflammatory Agents - chemistry | Antioxidants - administration & dosage | RAW 264.7 Cells | Antiparkinson Agents - administration & dosage | Mice | Kinetics | Oxidative Stress - drug effects | Antiparkinson Agents - metabolism | Catalase - chemistry | Drugs | Drug delivery systems | Proteases | Analysis | Antiparkinsonian agents | Vehicles | blood-brain barrier | neuroinflammation | exosomes | catalase | oxidative stress | Parkinson’s disease
Journal Article
PloS one, ISSN 1932-6203, 2014, Volume 9, Issue 6, p. e98961
Journal Article
PloS one, ISSN 1932-6203, 2013, Volume 8, Issue 4, p. e61700
Journal Article
Current Pharmaceutical Design, ISSN 1381-6128, 02/2011, Volume 17, Issue 5, pp. 489 - 507
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 05/2016, Volume 113, pp. 198 - 213
Thiazolo[4,5-d]pyrimidines are fused heterocyclic ring-systems that can be viewed at the first glance as purine isosteres. They are the 7 thia-analogs of... 
Immunomodulator | Antimicrobial | Thiazolo[4,5-d]pyrimdines | Chemokine receptor | Corticotropin Releasing Factor (CRF) ligands | Anti-inflammatory | FRACTALKINE RECEPTOR CXCR1 | CHEMISTRY, MEDICINAL | POTENTIAL ANTI-MICROBIALS | CXCR2 ANTAGONISTS | HUMAN CYTOMEGALOVIRUS | PYRIMIDINES | CANCER | ANTIMICROBIAL EVALUATION | ACTIVITY IN-VITRO | AGENTS | DERIVATIVES | Antiviral Agents - pharmacology | Anti-Infective Agents - pharmacology | Antineoplastic Agents - chemical synthesis | Humans | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Antineoplastic Agents - chemistry | Drug Discovery | Anti-Infective Agents - chemical synthesis | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Receptors, Corticotropin-Releasing Hormone - antagonists & inhibitors | Chemokines - antagonists & inhibitors | Thiazoles - chemical synthesis | Antiviral Agents - chemistry | Anti-Infective Agents - chemistry | Antiviral Agents - chemical synthesis | Thiazoles - chemistry | Antineoplastic Agents - pharmacology | Molecular Structure | Thiazoles - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis | Sulfur compounds | Antiviral agents | COX-2 inhibitors | ACTH | Drugstores | Cyclic adenylic acid | Homeopathy | Materia medica and therapeutics | Antiparkinsonian agents | Heterocyclic compounds | Pharmacy | Therapeutics | Drug discovery
Journal Article